A phase 1/2 study of STP938, a first-in-class inhibitor of CTP synthase 1, in patients with relapsed/refractory B or T cell lymphoma
Authors
Patel, M. R.Ahearne, M.
Linton, Kim M
Fox, C.
Lewis, D. J.
Higgins, M.
Schwartz, B. E.
Beer, P. A.
Tees, M. T.
Affiliation
Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FLIssue Date
2023
Metadata
Show full item recordCitation
Patel MR, Ahearne M, Linton K, Fox C, Lewis DJ, Higgins M, et al. A phase 1/2 study of STP938, a first-in-class inhibitor of CTP synthase 1, in patients with relapsed/refractory B or T cell lymphoma. Journal of Clinical Oncology. 2023 Jun;41(16). PubMed PMID: WOS:001053772005456.Journal
Journal of Clinical OncologyDOI
10.1200/JCO.2023.41.16_suppl.TPS7591Additional Links
https://dx.doi.org/10.1200/JCO.2023.41.16_suppl.TPS7591Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1200/JCO.2023.41.16_suppl.TPS7591